Tirzepatide

A new generation of weight loss and hypoglycemic drugs, Tirzepatide, came out. In addition to activating GLP-1R, Tirzepatide also activates GIPR, reducing caloric intake and increasing energy expenditure.

The safety profile of Tirzepatide is similar to that of other incretins. A meta-analysis that included 7 randomized controlled trials showed that gastrointestinal reactions caused by Tirzepatide, such as nausea, diarrhea, and constipation, were mostly mild to moderate.

There is another Active Pharmaceutical Ingredient Semaglutide CAS 910463-68-2 for weight management.

GLP-1 and GIP are both incretin hormones that regulate glucose metabolism and insulin secretion in the body.GLP-1/GIP receptor agonists help control blood sugar and can also help patients slow down digestion, making patients feel more full after eating and helping to lose weight by eating less.
● GLP-1 regulates glucose levels primarily by stimulating glucose-dependent insulin secretion, and slowing gastric emptying.
It can also reduce food intake by promoting satiety.
● GIP is rapidly produced upon ingestion of food and stimulates insulin secretion to regulate blood sugar.

A paper published in the Nature sub-journal Nature Metabolism titled: The incretin co-agonist Tirzepatide requires GIPR for hormone secretion from human islets found different effects of Tirzepatide in mouse and human islets: in mouse islets Tirzepatide mainly passes through GLP1R Stimulates insulin secretion, however in human pancreatic islets Tirzepatide stimulates insulin secretion through GLP1R and GIPR. This ingredient also enhances somatostatin secretion from human pancreatic islets.

Once-weekly dosing of Tirzepatide has demonstrated superior efficacy compared with basal insulin therapy in improving glycated hemoglobin (HbA1c) and postprandial blood glucose levels in patients with type 2 diabetes.

Semaglutide reduced HbA1c by an average of 2.0%, 2.2%, and 2.3%, respectively. On the other hand, CAS:910463-68-2 reduced HbA1c by an average of 1.9%. Regarding weight loss, an average weight loss of 17, 21, and 25 pounds, respectively, compared to a baseline weight of 207 pounds. In comparison, Semaglutide resulted in an average weight loss of 13 pounds. Therefore, this Active Pharmaceutical Ingredient showed better hypoglycemic and weight loss effects.